Clarus Therapeutics Holdings Inc.

04/22/2022 | Press release | Archived content

Correspondence (Form CORRESP)

CORRESP

April 22, 2022

VIA EDGAR

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Attn: Michael Davis

Re:

Clarus Therapeutics Holdings, Inc.

Registration Statement on Form S-1 (File No. 333-264231)

Ladies and Gentlemen:

As the underwriter of the proposed offering of Clarus Therapeutics Holdings, Inc. (the "Company"), we hereby join the Company's request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 9:00 a.m., Eastern Time, on April 25, 2022, or as soon thereafter as is practicable.

The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very truly yours,
Maxim Group LLC
By: /s/ Clifford A. Teller
Name: Clifford A. Teller
Title: Head of Investment Banking, Executive Managing Director